207_Combined course Presentations
EORTC 62931
• Results – No difference in 5-year OS (chemo 66·5%, control 67·8%)
• Conclusions “Future studies should focus on patients with larger, grade III, and extremity sarcomas”
Woll PJ, et al. Lancet Oncol. 2012;13(10):1045-54
Made with FlippingBook